NICE poised to turn down three ulcerative colitis drugs

The UK's National Institute for Health and Care Excellence is planning to keep three ulcerative colitis medications off the National Health Service formulary. PharmaTimes reports that the agency expects to turn down Janssen's Remicade (infliximab) and Simponi (golimumab) and AbbVie's Humira (adalimumab) for moderate-to-severe UC cases because evidence does not show them to be cost-effective interventions compared to what is already available.

PT says final guidance regarding these medications is expected in January 2015.